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Abstract 
 
Objectives 
 
Health technology assessments typically include a systematic review of clinical efficacy 
evidence and a cost-effectiveness model.  The development of the model always requires 
additional information beyond clinical efficacy.  Depending on the timing, size and number of 
information requirements,   the researcher faces considerable difficulties ensuring that 
reviewing activity to inform model development is both timely and systematic. There is a 
tension in terms of the need to ensure that this process is transparent and reproducible. 
This paper uses qualitative methods to identify these issues and to explore options for their 
resolution. 
Methods 
 
A focus group was held with 1 7experienced systematic reviewers, information specialists 
and health economic modellers. Framework analysis was used to analyse themes within the 
qualitative data. 
Results 
 
Six key themes were identified including: 1) problem structuring, 2) current practice, 3) 
adequate information, 4) timing, 5) ideal practice and 6) areas for further research. 
Reviewing, searching and modelling were seen as integrated tasks and the respondents felt 
that the whole team should be involved in structuring the decision problem. Good 
communication was deemed to be essential with more time spent on the most important 
information requirements. Assessments of the quality and relevance of information were also 
considered important by the focus group members.  Future research needs include training 
for focussed searching, problem structuring, quality assessment and the validation of 
parameter estimates. 
Conclusions 
 
This preliminary investigation highlights numerous concerns and potential deficiencies in the 
process of identifying, selecting and using evidence to inform models. Further guidance is 
required  to  ensure  that  such  research  activity  is  transparent,  timely  and  rigorous. 
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Introduction 
 
Health technology assessment (HTA) reports, such as those used to inform evidence based 
decisions on the effectiveness of healthcare interventions, typically involve the development 
of a cost-effectiveness model in addition to a systematic review of the clinical efficacy 
evidence.  The review is usually structured according to a focussed question which defines 
the populations, interventions, comparators and outcomes (PICO) of interest. The cost- 
effectiveness model addresses the same question but within an analytical framework that 
takes into account broader issues relating to the decision problem. The purpose of modelling 
is to draw together all relevant evidence and bring this to bear on the decision problem. By 
its very nature the development of the health economic model requires additional information 
beyond clinical efficacy as illustrated in Figure 1. 
 
 
 
 
 
 
Figure 1. Types of parameter values 
 
 
 
 
Reimbursement decisions are made on the basis of a broader set of issues over and above 
simply “does it work”.  The way in which this is done can have a fundamental impact on the 
results of the model and ultimately the decision outcome.  Whilst clear methods have been 
developed for reviewing efficacy evidence (1, 2), the same is not true for other types of 
evidence which are used as sources of evidence to inform model parameters. 
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A number of issues need to be considered when reviewing evidence to inform the 
specification and population of cost-effectiveness models.   Timelines for HTA may be 
restrictive so efficient methods are needed. In addition the methods need to be systematic, 
transparent and reproducible with attempts made to reduce bias in order to produce more 
reliable results.  If model results are to be considered credible, then researchers need to be 
transparent about how that model came about and why certain inputs should be considered 
reliable.   Sources of evidence may include: randomised controlled trials, observational 
evidence  and  other  clinical  studies,  registry  databases,  elicitation  of  expert  clinical 
judgement,  existing  cost-effectiveness  models,  routine  data  sources,  health  valuation 
studies, grey literature and other sources. Although reviewing processes are often used to 
identify data for economic models it is less usual for model reports to describe and justify 
how they have identified and synthesised the evidence beyond the efficacy data or for 
reports to set out a priori criteria against which to assess the quality of the evidence (3). 
Methodological guidance from  the  National Institute  for  Health  and  Clinical  Excellence 
(NICE) is vague, stating: “For all parameters (including effectiveness, valuation of HRQL and 
costs) a systematic consideration of possible data sources is required” (4).  This absence of 
clarity presents considerable challenges to organisations submitting evidence to NICE as the 
definition of what is relevant within a model will differ between decision problems. 
 
 
 
Information specialists, systematic reviewers and health economic modellers are all involved 
in producing health technology assessments although the level of involvement for each in 
identifying evidence to inform models will vary by project and centre.   Depending on the 
timing  and  size  of  the  requests  for  additional  information  there  can  be  considerable 
difficulties ensuring that the necessary information is reviewed in a timely and systematic 
fashion.  There is tension between available time and resources to develop models and the 
need to ensure transparency, reproducibility and rigour in the methods used to draw together 
information to structure and population them.  Populating certain elements of a model may 
require different levels of resource depending on their importance. 
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Although some of the issues surrounding reviewing evidence for models have been 
highlighted in detail (5-10) there appears to be very little formal guidance with regard to best 
practice in this area.  Cooper et al (5) state that little is known about current practice 
regarding evidence identification and selection strategies, except that it is neither uniform nor 
transparent.  Criticisms include inadequate reporting on how evidence was identified, a lack 
of justification regarding how evidence was selected for use in the model and a lack of 
quality assessment of the evidence used.  Phillips et al (6) suggests that the search process 
and the methods for ascertaining parameter estimates should be clearly described and that 
in principle the results should be reproducible by another researcher.  A feasibility study on 
searching for model parameters (11) concluded that determining the most appropriate 
resources to search was dependent on the model question and that multiple database 
searching using focused search strategies may prove more effective in finding relevant data 
than thorough searches of a single database.  Searching should be efficient, that is given 
resource constraints searching should focus on those parameters that are expected to have 
the largest influence on the results of the model, although whether or not a parameter is 
important to the model results will be to a large extent dependent on what has been 
assumed for the other model parameters.  Coyle and Lee (7) demonstrated that using 
different sources of data can have a large impact on the results and highlighted that there is 
lack of agreement as to what constitutes good evidence for specific data inputs in economic 
models.  Chilcott et al (12) argue that one potential source of errors in health technology 
assessment models is the separation of the information gathering, reviewing and modelling 
functions. 
 
 
 
Owing to time and resource constraints it may be necessary to use rapid review methods to 
identify and select evidence to inform certain model parameters.  Watt et al (13) raise the 
point that as with the use of rapid review methods in other areas a key issue is to increase 
the transparency of the methods used for each review.  The basic principles of systematic 
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reviewing: searching, appraisal, synthesis and analysis (14) may be applicable to the 
identification of model parameters as a full systematic review may be neither feasible nor 
necessary.  This aim of this paper was to identify relevant key issues associated with 
reviewing evidence for cost-effectiveness models, particularly with respect to informing 
estimates for model parameters, to make recommendations for good practice and to identify 
areas in which further research is required. 
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Methods 
 
A focus group was held with 17 researchers with extensive experience in health technology 
assessments including five systematic reviewers, two information specialists and nine health 
economic modellers in January 2010.  The researchers were all from the School of Health 
and Related Research (ScHARR) at the University of Sheffield.  A range of different people 
with different areas and levels of expertise were purposively invited to attend the focus group 
in order to reflect the breadth of input into the model development process.  Ethics approval 
was obtained from the University of Sheffield.  A topic guide was developed to structure the 
discussion within the focus group.  The topic guide included questions covering current 
practice, adequate information, the timing at which reviewing activity takes place, ideal 
practice and areas in which further research is required.  The focus group was facilitator led 
(EK) and was recorded using digital media with the recordings transcribed verbatim. 
Qualitative framework analysis (15) was used to draw out themes from the transcribed data. 
The transcripts were coded and a framework approach applied.  A subsequent seminar was 
held in June 2010 and used as a member checking device.  All of the 17 researchers were 
invited to the seminar where further discussions were held on each of the key themes 
identified in the focus group. 
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Results 
 
Framework analysis, using the topic guide questions as an initial framework was used to 
draw out the focus group themes. Six main themes were identified from the focus group: [1] 
problem structuring, [2] current practice in model parameter reviewing, [3] determining when 
there is adequate information, [4] appropriate timing for the specification of parameters, [5] 
ideal practice for identifying evidence for model parameters and [6] areas identified for future 
research. These themes were further separated into subthemes. 
 
 
 
Problem structuring 
 
Structuring the decision problem and specifying which parameters are relevant in 
representing the decision problem are important parts of the process according to the focus 
group participants.   Respondents stated that some of the important parameters could be 
anticipated from the outset and that problem structuring should begin early enough to 
facilitate shared planning and understanding within the project team.   A  key issue for 
problem structuring was defining what constitutes a relevant parameter and what process 
was required to uncover that relevance.  It was suggested that the model structure and 
definition of model parameters needs to take place before systematic attempts are made to 
identify values for the parameters.  One respondent suggested that the main objective of 
problem structuring activity is to develop a model that is generalizable to real world practice; 
this was deemed to be a task for the whole research team rather than the solely the modeller 
or economist.   Respondents felt that an evidence-based conceptual model should be 
explicitly developed and that searching and reviewing is required to inform this development. 
 
 
 
Current practice 
 
Respondents reported that at the beginning of the modelling process the team may start off 
with background reading and clinical input to determine the disease natural history and 
develop a general understanding of the area and then think about which evidence sources 
should be consulted to inform model parameters.  One modeller felt that the whole process 
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of populating relevant parameters can be quite subjective so it is important that there is 
transparent and adequate reporting of the decision process for selecting parameter values. 
Not only is it important to report how the searching was done and the search results but 
there needs to be a clear reporting of the systematic process used to select the parameters 
values  that  are  used.    This  should  include  quality  assessment.    Respondents  raised 
concerns about the quality of rapid searching done by individuals who have not been 
formally trained as information specialists. 
 
 
 
The choice of clinical experts was felt to be important for identifying information to inform 
model parameters as this will have an impact on the appropriate specification and population 
of model parameters. Clinicians were thought to vary considerably with respect to their level 
of expertise in interpreting evidence and their opinions concerning the use of specific 
technologies.   Sometimes two or three clinicians acted as project advisors and attended 
project meetings to allow the opportunity for extensive discussion aimed at reaching a 
consensus of opinion.  Whilst it was acknowledged that the choice and use of expert opinion 
required caution, expert clinical advice was considered to be an essential and ongoing part 
of the model development process although participants did not mention asking clinical 
experts to review identified model parameters. 
 
 
 
The dynamics of the research team were considered important and this was felt to vary 
across individual projects and across different research centres.  Some roles may be shared 
among the team.  The background and level of expertise of the reviewer was considered to 
have a relevant impact on how the model is developed.  There was reported variation in the 
degree of separation between the tasks of reviewing and the broader process of model 
development and in the extent to which these processes were integrated.  Although it was 
mentioned that systematic reviewers have considerable experience in reviewing large 
amounts of material, some modellers mentioned that they felt that sometimes they had to 
find all parameter values themselves. In contrast, for the sake of efficiency, one modeller felt 
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that it may be more appropriate for the modeller to identify and appraise evidence for model 
parameters. 
 
 
 
Some respondents stated that they develop a list of tasks for the research team at the 
beginning  of  a  project  and  divide  the  tasks  between  the  reviewer  and  the  modeller 
depending on expertise and available time. It was felt that for some parameters the modeller 
was better placed to find appropriate values whilst for others this activity would be more 
appropriately undertaken by the reviewer. The respondents’ experiences with respect to this 
division of tasks seemed to vary between projects. The process was described as “iterative” 
as more information may be needed later as the model is developed.  Respondents stated 
that the team becomes more focussed on the parameters that are shown to be sensitive and 
new issues are identified throughout the model development process as attempts are made 
to reflect parameter uncertainty.  However an issue was also raised that the sensitivity of 
one parameter will to some extent be dependent on the values of the other parameters. 
Therefore caution should be advised in using this approach to focus reviewing efforts.  A 
common view amongst the focus group respondents was that the reliance on simple 
sensitivity analysis (e.g. one-way or restricted multi-way analysis) represents an insufficient 
basis for assessing parameter importance and may indeed produce misleading findings 
depending on the extent to which other model parameters have been systematically 
identified, selected and used within the model. All respondents agreed that it was 
inappropriate for the systematic review to be undertaken in complete isolation and then 
handed over to the modeller with no communication between the two; instead it was agreed 
that this needs to be an integrated process. 
 
 
 
Frequent project team meetings were suggested as an opportunity for discussion and for 
making decisions concerning the need for more information.  For example, after identifying 
parameters that have an impact on the model results, discussions about a more systematic 
reviewing approach for that parameter may be needed.   Some reviewers said that they 
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flagged up information that they thought would be important for the model but were not clear 
as to how or if this information was used by the modeller. 
 
 
 
Adequate information 
 
A specific focus of the discussion within the focus group concerned what constitutes 
“adequate” information.  One issue concerned the danger of relying on only one clinical 
advisor.   Although clinical advisors were seen as an important source of information and 
potentially more appropriate than the use of routine data sources or the literature for some 
but not all parameters, more than one expert was needed and there had to be a level of 
understanding of the condition on the part of the team to ensure that the most appropriate 
decisions were made regarding model parameters.  This was also felt to some extent to be 
dependent on geographical variation and local enthusiasms for particular technologies.  The 
use of an expert panel was suggested as a possible means for avoiding this potential source 
of bias.  Also mentioned was the need to ensure that all levels of health care delivery were 
represented, for example hospital specialists as well as GPs as opinions on treatments and 
approaches can be quite different across different settings.   Respondents also raised 
concerns regarding determining the level of variation in the pathway of care and the extent to 
which the model should reflect this. A related issue raised by the respondents concerned 
tensions between internal and external validity in models, with particular reference to the 
potential gap between costs and outcomes of treatments sourced from clinical trial data and 
actual clinical practice.   The respondents suggested that attempts need to be made to 
ensure that the uncertainty around each of the parameter estimates is characterised 
appropriately. 
 
 
 
A major concern raised by the respondents was that a team could potentially make an 
assumption that they had identified all relevant information for a model parameter when in 
fact they may have missed important evidence.   Conversely it was agreed that 
comprehensiveness was not the goal as it was not necessarily important to find all sources 
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of information nor would there be time due to the constraints of most projects.  Finding the 
best source of evidence was an issue felt to be sometimes down to serendipity and 
sometimes down to taking the time to determine what was the most reliable or realistic 
source of information.  Respondents felt that there was a difference between transparency 
and credibility in that the wrong model might be developed and yet be clearly reported.  As 
well as identifying the most suitable sources of information it was considered also important 
to report the thought processes involved in the development of the model and why specific 
choices  had  been  made.    Quality  assessment  of  evidence  was  mentioned  as  being 
important. 
 
 
 
Timing of reviewing activity 
 
The respondents noted that judgements regarding the importance of specific parameters are 
sometimes made quite late in the development of a model and respondents suggested that it 
can be very difficult to plan for this in advance.  When one parameter is changed another 
parameter can suddenly become more important to the results. Some can be identified early 
on by putting estimates into the model but this approach needs to be treated with caution. 
Judgements need to be made regarding the efficient use of time and resources in such 
cases.  There is a danger that parameter values may be identified in a less than systematic 
way due to these constraints. One recommendation was that it is important to plan and give 
the team an idea early on as to what additional parameters values to be looking for.  The 
development of a conceptual model at the start of the project was considered very useful for 
this reason and it was felt to be important to incorporate some contingency time for 
unexpected parameter values. 
 
 
 
Ideal practice 
 
Several points were identified regarding ideal practice.  First, problem structuring methods 
should be considered in order to identify what is relevant early on in the modelling process. 
Communication was felt to be very important and everyone in the team should be involved in 
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the development of the model structure from the beginning and work closely together.  This 
was considered to be an iterative process though the level of iteration differs between 
projects and teams.  It was felt that iterative team working helped to ensure that the most 
relevant parameter values were identified.      The reviewers are also aware of the 
requirements of the model during data extraction for the clinical efficacy review; this was 
seen as a benefit of structuring the process in this way.  It was considered particularly useful 
if at least some members of the team have expertise in the disease area.  Reporting of the 
process of reviewing for model parameters was thought to be essential in demonstrating that 
it had been done in a systematic and reproducible fashion. 
 
 
 
Some modellers stated that they would like to  be  more involved in  the searches that 
informed the model.   For some projects there may be a need for focussed searches. 
Although not every piece of evidence for every model parameter will be identified, decisions 
need to be made as to the type of searching and sifting that the time constraints of the 
project allow. 
 
 
 
Also mentioned was the possibility of “tagging” potentially relevant sources during the sifting 
of references.  At the start of a project when reviewers are sifting references for the clinical 
efficacy review they can also look for other relevant references which may be used for 
populating model parameters.  If there was a list of parameters, keywords could be used to 
aid the rapid identification of relevant studies for specific parameters. One potential problem 
with tagging was the possibility of the reviewer missing potentially appropriate information 
sources and the modeller assuming that there was no relevant information in the database of 
references because it had not been identified by the reviewer. 
 
 
 
Respondents felt that forward planning was important where possible. Although requests for 
more information may come late on in the project, some of these needs can be anticipated. 
One final suggestion was for a repository for key parameter values. 
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Areas in which further research is required 
 
Several recommendations for further research were identified by respondents.  There was 
considerable support for the need for training for rapid searching methods.  Although ideally 
searches would be undertaken by information specialists this was not always feasible and 
other members of the team felt that training in this area would be helpful.  It was also 
suggested that it would be useful to have some guidelines concerning where to find 
information such as a list of websites and a hierarchy of information sources.  Training was 
also needed for scoping searches and focussed searches. 
 
 
 
More research was considered necessary regarding methods for problem structuring and 
ways this process could be communicated.  Also mentioned were research into methods for 
decision making processes around the selecting and reviewing of evidence for model 
parameter values.  Another research area mentioned concerned methods for establishing 
the standard care pathway or a representative selection of care pathways.   Quality 
assessment methods for different study types, particularly rapid quality assessment tools 
were also suggested as were methods for validating model parameter estimates.   Finally, 
research into how the use of clinical expert opinion should be managed and incorporated 
into the model development process was suggested. 
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Discussion 
 
Summary of main issues identified 
 
The purpose of this paper was to identify prevalent issues and constraints surrounding the 
systematic consideration of evidence sources used to inform health economic models. 
Inevitably, comprehensive, systematic reviewing of the evidence for all model parameters is 
not  possible  due  to  time  and  resource  constraints.     However  the  well  established 
components of systematic reviewing searching, appraisal, synthesis and analysis can be 
utilised to maximise transparency in the choice of parameter values as far as is possible. 
 
 
 
The focus group highlighted that activities surrounding reviewing for model parameters 
represent a central element of model development. Reliance on simple sensitivity analysis 
was felt to be an insufficient basis for assessing parameter importance and may result in the 
production of misleading findings depending on the extent to which other model parameters 
have been systematically identified, selected and used within the model. Further, the extent 
of  a  given  parameter’s importance  upon  the  model  results  may  change  as  the  other 
elements of the model are further developed and refined.  Claxton (16) argues that adoption 
decisions should be made on the basis of mean costs and health outcomes; in principle a 
single model parameter which is not subjected to formal searching, synthesis and analysis 
could produce misleading estimates of costs and outcomes and potentially result in 
inappropriate policy decisions. The best measure of the credibility of a model’s parameters is 
the legitimacy of the process through which the evidence has been identified, selected and 
implemented rather than whether it matters to the results at some point in time during model 
development. This view was directly reflected in the focus group responses. 
 
 
 
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has 
produced good practice in modelling guidance (17, 18) which covers some of the issues 
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outlined in this research.  However, little guidance is given where a full systematic review for 
model parameters is not possible due to time or resource constraints. 
 
 
 
A  further  finding  arising  from  the  discussions  concerned  the  nature  of  the  model 
development process. It became clear from the respondents that the definition of best 
practice for reviewing evidence to inform model parameters cannot be entirely detached 
from problem structuring activities to determine which parameters are relevant to the 
particular decision problem. Given this interrelationship, the focus group respondents 
suggested that parameter reviewing activity should not lie solely with the reviewer, nor solely 
with the modeller; instead the respondents suggested that this should be considered as a 
joint process and that the organisational infrastructure should reflect the need for joint 
working in this area. 
 
 
 
Implications for practice 
 
The methodological and practical issues from the focus group give rise to a number of 
implications for the practice of health economic model development. 
Recognition of the joint relationship between model development and reviewing activity: 
Model specification and model parameterisation are intertwined and should not be treated as 
separate processes; they are both directly concerned with ensuring the credibility of results 
drawn from the model. Model development should be considered as a broader process than 
simply model implementation and programming, instead including all aspects of evidence 
identification, selection and use in addressing the decision problem. 
Improved communication and training: There is a need for reviewers and information 
specialists to understand the principles of health economic modelling as well as a need for 
modellers to understand the principles of searching and systematic reviewing. This may 
have training implications for modellers, information specialists and reviewers. 
Transparency and consistency: There is considerable variation in the way that models are 
developed and in how reviewing for model parameters is undertaken.   However, greater 
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degrees of consistency and transparency are desirable in ensuring model credibility. The 
identification, selection and use of particular evidence sources to inform model parameters 
should be explicitly justified. It is reasonable to further argue that decisions concerning the 
model specification, that is the definition of which parameters are relevant within the model, 
should also be explicitly described in the form of one or more conceptual models. 
 
 
 
Areas for future research 
 
It is important to recognise that this research is based on one focus group in one research 
centre, and as such, the findings of this study should be considered exploratory in nature. 
Current practice in reviewing model parameters, and indeed the broader process of model 
development may vary between academic centres and other health outcomes and 
consultancy groups.  It is essential to explore these issues in more depth with other centres 
who may have different approaches to the modelling process.  Nevertheless several areas 
where more research is needed were identified.  The first involves the use of problem 
structuring methods for the identification, specification and prioritisation of relevant 
parameters.  Another area of research identified is the systematic identification of evidence 
to inform model parameter estimates.  This includes guidance on appropriate searching 
methods.   Research into methods for reviewing model parameter data in a systematic 
fashion are also needed and include critical appraisal and rapid review methods.  Finally, 
guidance in the appropriate reporting of review methods and decisions and judgements 
made for the identification and selection of evidence are needed. 
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